Mark A Socinski

发表

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Nick Thatcher, Shengyan Hong, Jacek Jassem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.

Stefano Monti, Giovanni Parmigiani, Matthew Meyerson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies.

M. Socinski, T. Stinchcombe, Mark A Socinski, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapeutic management of stage IV non-small cell lung cancer.

David E Morris, M. Socinski, R. Lilenbaum, 2003, Chest.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Current treatments for advanced stage non-small cell lung cancer.

M. Socinski, T. Stinchcombe, Mark A Socinski, 2009, Proceedings of the American Thoracic Society.

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

Michael J Schell, Martha Moore, Ji-Hyun Lee, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measuring the side effects of taxane therapy in oncology

David Cella, Stacie Hudgens, M. Socinski, 2003, Cancer.

Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.

M. Socinski, Mark A Socinski, 2011, Cancer treatment reviews.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.

M. Socinski, Mark A Socinski, Liza C Villaruz, 2014, Lung cancer.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

K. Nackaerts, M. Socinski, F. Shepherd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Scott M Lippman, Jean-Yves Douillard, 2008, The Lancet.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.

M. Socinski, Carrie Lee, Mark A Socinski, 2007, Reviews on recent clinical trials.